HMA WGEO Rapid Alert Form
Falsified or illegal product found in the illegal supply chain

Unique Reference N0 (to be filled by Member State issuing alert): MED-2022- 166					
Date: 30/06/2022	Time:		Initials:		
Please complete sections 1 to 5 providing as much information as possible.					
1. REPORTING PERSON					
Name:		Position:			
Organisation:					
Address:					
Telephone No:			Ext:		
e-mail address:					
2. PRODUCT DETAILS					
Product name: CURACNE (Active ingredient : isotretinoïne)					
Manufacturer: Pierre Fabre Dermatologie					
Supplier: Pierre Fabre Dermatologie					
Legal status: Banned ☐ Falsified ☐ Unlicensed ☐ Stolen ☒					
Dosage form: soft capsules					
Strength:5 mg, 20 mg, 40 mg					
Batch / lot no: CURACNE 5 batch HR309400, CURACNE 20 HR343203;					
CURACNE 40 HR381712 Is batch number genuine: Yes ⊠ No □					
If yes to the above, advise batch destination country: Tunisia (Curacne 5, 20					
and 40) and others countries (Curacne 20 and 40), these batches having					
been distributed in part to wholesale distributors for export in France and will					
also be distributed for the remaining stock					
Expiry date: CURACNE 5 batch HR309400 per 02/2024					
CURACNE 20 HR343203 per 06/2024					
CURACNE 40 HR381712 per 01/2025					
Language of packaging: French					
Date of discovery: 07 may 2022					

Details of discovery: CURACNE 5 batch HR309400 : 640 medicine boxes stolen					
CURACNE 20 HR343203 : 1280 medicine boxes stolen					
CURACNE 40 HR381712 : 1600 medicine boxes stolen					
Theft during transport between Vitrolles (France, loading 4 may 2022) and Tunis					
(Tunisia) via Marseille (4 may 2022 loading on a boat). Discovery of the theft upon the					
arrival at Central Pharmacy of Tunis (7 may 2022)					
Analysed: YES ☐ NO ☒					
If yes, result of analysis:					
3. DISTIRUBUTION METHOD					
Internet: YES NO					
Internet:	Non internet, advise full details:				
URL:	Tron internet, advise fair details.				
Website address:					
Other details:					
Currency of payment:					
Has product reached patients/consumers?					
4. RISK TO PUBLIC HEALTH					
Adverse reactions: YES ⊠ NO □					
If yes, please advise details: if the product is not used under strict medical					
supervision (many side effects and teratogenic product)					
Medical assessment details:					
5. NEED FOR PUBLICITY					
Are you making a public statement? YES ⊠ NO □					
Are you issuing a press release? YES NO ⊠					
Are you recalling product? YES ☐ NO ☒					
If yes to any of the above, when do you intend to take action?					
Information on wholesale distributors in France					
6. DISSEMINATION					
Are you content for this Rapid Alert to be shared outside WGEO membership?					
YES ⊠ NO ☐ (please see below)					
If yes, please specify which of the below you are content for this to be shared					

with (you may tick more than 1 box)		
Law Enforcement ⊠ Industry Security ☐ Trade Associations ☐		
Traders ☐ Customs (nominal data) ☐ Other ☐		
Please specify		
7. PHOTOGRAPH		
If possible, please attach a photograph of the product.		





